12-10-01

"Express Mail" Label No.: EV0531

Date of Deposit: 12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kenneth W. Dobie and Mark P. Roach

For: Antisense Modulation of NOD1 Expression

BOX SEQUENCE

Assistant Commissioner for Patents

Washington DC 20231

## PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find the following:

- · The specification of the above-referenced patent application;
- · An executed Declaration or Oath and Power of Attorney;
- An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- · Statement to Support Filing and Submission of DNA/Amino Acid Sequences in
- Accordance with 37 CFR § § 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- · An Information Disclosure Statement with references; and
- . Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE			- W	\$370.00
Total Claims	20 - 20 =	0	x \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- · the amount of \$410.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filling fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- $\cdot$  any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed

Date: December 5, 2001

Donna T. Ward

Registration No. 48,271 Isis Pharmaceuticals, Inc.

Please address all correspondence to: Jane Massey Licata or Kathleen A. Tyrrell Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515

1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Kenneth W. Dobie and Mark P. Roach

Serial No.: not yet assigned Filing Date: herewith

Title: Antisense Modulation of NOD1 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C., 20231

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. \$1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. \$1.821(c) and (e), respectively, are the same.

Date: December 5,2001

Respectfully submitted,

Donna T. Ward

Registration No. 48,271 Isis Pharmaceuticals, Inc.

## Please address all correspondence to:

Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515